类器官技术在乳腺癌研究中的现状及应用

doi:10.11958/20231745

天津医药 ›› 2024, Vol. 52 ›› Issue (6): 668-672.doi: 10.11958/20231745

• 综述 • 上一篇

类器官技术在乳腺癌研究中的现状及应用

陈芷彦¹^,²(), 伍秋苑¹^,², 邓裕华², 周丹¹^,²^,^△()

1 广东医科大学第一临床医学院（邮编524000）
2 佛山市第一人民医院

收稿日期:2023-11-14 修回日期:2023-12-07 出版日期:2024-06-15 发布日期:2024-06-06
通讯作者: ^△E-mail：zhoudanms@hotmail.com
作者简介:陈芷彦（2000），女，硕士在读，主要从事乳腺癌的手术治疗方面研究。E-mail：1067492540@qq.com
基金资助:
广东省基础与应用基础研究基金区域联合基金项目（地区培育项目）(2022A1515140091);广东省中医药局中医药科研项目(20231324)

Status and application of organoid technology in breast cancer research

CHEN Zhiyan¹^,²(), WU Qiuyuan¹^,², DENG Yuhua², ZHOU Dan¹^,²^,^△()

1 The First Clinical College, Guangdong Medical University, Zhanjiang 524000, China
2 The First People’s Hospital of Foshan

Received:2023-11-14 Revised:2023-12-07 Published:2024-06-15 Online:2024-06-06
Contact: ^△E-mail: zhoudanms@hotmail.com

陈芷彦, 伍秋苑, 邓裕华, 周丹. 类器官技术在乳腺癌研究中的现状及应用[J]. 天津医药, 2024, 52(6): 668-672.

CHEN Zhiyan, WU Qiuyuan, DENG Yuhua, ZHOU Dan. Status and application of organoid technology in breast cancer research[J]. Tianjin Medical Journal, 2024, 52(6): 668-672.

摘要/Abstract

摘要：

类器官能够很好地模拟肿瘤的异质性，包括肿瘤微环境、免疫反应等，这有助于更准确地预测患者对药物的反应和治疗效果，且可以在药物进入体内前进行药物筛选，从而节约临床试验的时间和成本。然而，类器官的研究仍面临一些挑战，如技术限制、伦理问题等。就乳腺癌类器官的研究进展，包括类器官的定义、发展历程、优势以及在乳腺癌研究中的应用进行综述。

关键词: 类器官, 乳腺肿瘤, 药物筛选, 个性化治疗

Abstract:

Organoids can well simulate the heterogeneity of tumors, including tumor microenvironment and immune response, which helps to more accurately predict patient responses to drug and treatment effects. Organoids can be used for drug screening before drugs enter body, thus reducing the time and cost of clinical trials. However, research on tissue-organoids still faces some challenges, such as technical limitation and ethical issue. This review mainly introduces the progress in the research of breast cancer organoids, including the definition of organoids, development history, advantages and application in breast cancer research.

Key words: organoids, breast neoplasms, drug screening assays, personalized medicine

中图分类号:

R655.8

参考文献 30

[1]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics,2022[J]. CA Cancer J Clin, 2022, 72(1):7-33. doi:10.3322/caac.21708.
[2]	GREENWALT I, ZAZA N, DAS S, et al. Precision medicine and targeted therapies in breast cancer[J]. Surg Oncol Clin N Am, 2020, 29(1):51-62. doi:10.1016/j.soc.2019.08.004.
[3]	LANCASTER M A, KNOBLICH J A. Organogenesis in a dish: modeling development and disease using organoid technologies[J]. Science, 2014, 345(6194):1247125. doi:10.1126/science.1247125.
[4]	SATO T, STANGE D E, FERRANTE M, et al. Long-term expansion of epithelial organoids from human colon,adenoma,adenocarcinoma,and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5):1762-1772. doi:10.1053/j.gastro.2011.07.050.
[5]	SATO T, CLEVERS H. SnapShot: growing organoids from stem cells[J]. Cell, 2015, 161(7):1700-1700.e1. doi:10.1016/j.cell.2015.06.028.
[6]	YANG B, WEI K, LOEBEL C, et al. Enhanced mechanosensing of cells in synthetic 3D matrix with controlled biophysical dynamics[J]. Nat Commun, 2021, 12(1):3514. doi:10.1038/s41467-021-23120-0.
[7]	WANG F, WEAVER V M, PETERSEN O W, et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology[J]. Proc Natl Acad Sci U S A, 1998, 95(25):14821-14826. doi:10.1073/pnas.95.25.14821.
[8]	JESPERSEN H, LINDBERG M F, DONIA M, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model[J]. Nat Commun, 2017, 8(1):707. doi:10.1038/s41467-017-00786-z.
[9]	ZHAO Y, SHUEN T, TOH T B, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy[J]. Gut, 2018, 67(10):1845-1854. doi:10.1136/gutjnl-2017-315201.
[10]	DIVOUX J, FLORENT R, JACOBS M, et al. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer[J]. BMC Cancer, 2023, 23(1):883. doi:10.1186/s12885-023-11362-8.
[11]	SACHS N, DE LIGT J, KOPPER O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1/2):373-386. doi:10.1016/j.cell.2017.11.010.
[12]	PRINCE E, CRUICKSHANK J, BA-ALAWI W, et al. Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids[J]. Nat Commun, 2022, 13(1):1466. doi:10.1038/s41467-022-28788-6.
[13]	HOGSTROM J M, CRUZ K A, SELFORS L M, et al. Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms[J]. J Biol Chem, 2023, 299(8):105021. doi:10.1016/j.jbc.2023.105021.
[14]	DEKKERS J F, WHITTLE J R, VAILLANT F, et al. Modeling breast cancer using CRISPR-Cas9-Mediated engineering of human breast organoids[J]. J Natl Cancer Inst, 2020, 112(5):540-544. doi:10.1093/jnci/djz196.
[15]	CHEW N J, LIM KAM SIAN T, NGUYEN E V, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models[J]. Breast Cancer Res, 2021, 23(1):82. doi:10.1186/s13058-021-01461-4.
[16]	VANDERVORST K, DREYER C A, HATAKEYAMA J, et al. Vangl-dependent Wnt/planar cell polarity signaling mediates collective breast carcinoma motility and distant metastasis[J]. Breast Cancer Res, 2023, 25(1):52. doi:10.1186/s13058-023-01651-2.
[17]	CAMPANER E, ZANNINI A, SANTORSOLA M, et al. Breast cancer organoids model patient-specific response to drug treatment[J]. Cancers (Basel), 2020, 12(12):3869. doi:10.3390/cancers12123869.
[18]	GUILLEN K P, FUJITA M, BUTTERFIELD A J, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology[J]. Nat Cancer, 2022, 3(2):232-250. doi:10.1038/s43018-022-00337-6.
[19]	JIANG T, ZHU J, JIANG S, et al. Targeting lncRNA DDIT4-AS1 sensitizes triple negative breast cancer to chemotherapy via suppressing of autophagy[J]. Adv Sci (Weinh), 2023, 10(17):e2207257. doi:10.1002/advs.202207257.
[20]	SOOSAINATHAN A, IRAVANI M, EL-BOTTY R, et al. Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine- and palbociclib-resistant ER+ breast cancers[J]. Cancer Res, 2024, 84(1):17-25. doi:10.1158/0008-5472.CAN-23-0650.
[21]	SAEKI S, KUMEGAWA K, TAKAHASHI Y, et al. Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin[J]. Breast Cancer Res, 2023, 25(1):21. doi:10.1186/s13058-023-01617-4.
[22]	YANG L, LIU B, CHEN H, et al. Progress in the application of organoids to breast cancer research[J]. J Cell Mol Med, 2020, 24(10):5420-5427. doi:10.1111/jcmm.15216.
[23]	ZHOU Z, CONG L, CONG X. Patient-derived organoids in precision medicine: drug screening,Organoid-on-a-Chip and living Organoid Biobank[J]. Front Oncol, 2021, 11:762184. doi:10.3389/fonc.2021.762184.
[24]	SHU D, SHEN M, LI K, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy[J]. Ann Med, 2022, 54(1):2581-2597. doi:10.1080/07853890.2022.2122550.
[25]	DONG S, MATOSSIAN M D, YOUSEFI H, et al. Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy[J]. Sci Rep, 2023, 13(1):11843. doi:10.1038/s41598-023-37058-4.
[26]	YANG M, GUAN T, CHEN C F, et al. Mesothelin-targeted CAR-NK cells derived from induced pluripotent stem cells have a high efficacy in killing triple-negative breast cancer cells as shown in several preclinical models[J]. J Immunother, 2023, 46(8):285-294. doi:10.1097/CJI.0000000000000483.
[27]	SONG R, MA S, XU J, et al. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR[J]. Mol Cancer, 2023, 22(1):16. doi:10.1186/s12943-023-01719-9.
[28]	NARAYAN P, PROWELL T M, GAO J J, et al. FDA approval summary:Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer[J]. Clin Cancer Res, 2021, 27(7):1842-1849. doi:10.1158/1078-0432.CCR-20-3652.
[29]	YANG Y S, JIN X, LI Q, et al. Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression[J]. Proc Natl Acad Sci U S A, 2022, 119(46):e2207201119. doi:10.1073/pnas.2207201119.
[30]	TSAI K K, HUANG S S, NORTHEY J J, et al. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity[J]. Nat Cancer, 2022, 3(6):734-752. doi:10.1038/s43018-022-00375-0.

类器官技术在乳腺癌研究中的现状及应用

Status and application of organoid technology in breast cancer research

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱刚明, 董永德, 朱瑞婷, 谭源满, 陶娟, 刘晓, 陈德成, 杨概. 磁共振弛豫时间定量成像预测乳腺浸润性导管癌分子亚型的价值[J]. 天津医药, 2024, 52(7): 770-774.
[2]	刘丹阳, 李永涛, 张海燕, 李林, 刘洋, 沈雷. 乳腺癌细胞条件培养基对骨髓间充质干细胞生物学行为的影响[J]. 天津医药, 2024, 52(5): 454-458.
[3]	谢皓冉, 李一浩, 刘成, 夏瑜婷, 裘圣蕾, 熊斌, 冯其贞. 医保DIP支付背景下乳腺癌腋窝淋巴结转移的预测因素探讨[J]. 天津医药, 2024, 52(11): 1193-1196.
[4]	孟繁露, 韩益明, 修继冬, 黄建永. 高通量自动化类器官芯片研究进展[J]. 天津医药, 2024, 52(1): 1-3.
[5]	徐桂颖, 李玉, 李雪, 刘怡萌, 陈怀永. 气道类器官研究哮喘中Lkb1调控上皮再生的机制[J]. 天津医药, 2024, 52(1): 11-15.
[6]	陈浩, 李蕊, 易菲, 周丽, 陈嘉琪, 朱璠, 管城艳, 吴娜. 小鼠小肠类器官炎症模型的构建[J]. 天津医药, 2024, 52(1): 16-21.
[7]	姜忠敏, 张春艳, 刘敏, 郑洁, 李艳霞, 仁青措, 孟纬, 刘晓智. 微乳头型肺腺癌类器官的构建及其靶向药物的筛选[J]. 天津医药, 2024, 52(1): 22-27.
[8]	司吴雪蓉, 蒋明. 类器官在癌症基础研究和临床转化中的应用[J]. 天津医药, 2024, 52(1): 28-32.
[9]	雷敏, 蔡春泉. 类器官在儿童遗传性疾病中的应用研究进展[J]. 天津医药, 2024, 52(1): 33-37.
[10]	孙可心, 肖雨倩, 万俊, 陈淑颖, 陈丽敏, 王岩, 白艳杰. 脑类器官技术及在脑卒中治疗中的应用进展[J]. 天津医药, 2024, 52(1): 38-43.
[11]	宋立成, 张宇涵, 余忠阔, 解立新. 气道类器官显微注射及极性反转模型的构建[J]. 天津医药, 2024, 52(1): 4-10.
[12]	吴海啸, 马文娟, 李之珺, 张超. 基于放射组学评估胸肌指数与乳腺癌骨转移患者预后关系的研究[J]. 天津医药, 2023, 51(9): 1007-1010.
[13]	杨娉娉, 张景, 陈红宇, 张淼, 周定安, 方文. 抑癌基因SASH1在乳腺癌中结合Vimentin并负性调节Vimentin的表达[J]. 天津医药, 2023, 51(9): 904-908.
[14]	赵津津, 王振宇, 马贞秀. circRASSF2靶向miR-1343-3p对乳腺癌MDA-MB-231细胞增殖和凋亡的影响[J]. 天津医药, 2023, 51(7): 713-717.
[15]	郝德, 李宽, 王建海, 岳青, 陈怀永. NO介导的代谢紊乱影响小鼠气道祖细胞增殖的机制研究[J]. 天津医药, 2023, 51(5): 477-481.